Santarus, Inc.
Grace Benedict is an accomplished pharmaceutical professional with extensive experience in the industry, currently serving as the Director of Pharmaceutical Sciences at Santarus, Inc. since 2003. In this role, Grace directed the development of analytical and bioanalytical strategies for pharmaceutical products, successfully authoring the Uceris® CMC NDA, which achieved regulatory approval and peak sales of $500M. Formerly, Grace held positions at Santarus as Senior Manager and Manager of Pharmaceutical Sciences, leading significant projects such as the successful manufacturing validation for a delayed release antibiotic and the Zegerid® commercial launch, earning the 2006 Santarus Leadership Award. Grace's career includes pivotal roles at Arizeke, Inc., Elan Pharmaceuticals, and Amgen, where contributions included establishing quality control processes, managing research projects, and significantly increasing laboratory throughput. Grace's expertise encompasses all aspects of pharmaceutical product development and regulatory compliance.
This person is not in any teams
Santarus, Inc.
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction ofremission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.